


1. (Twice Amended) A [residue of a] compound of formula I:



linked to [a residue of] a molecule comprising B-10, wherein X is CN, OH, CH₃, adenosyl or a molecule comprising B-10; or a pharmaceutically acceptable salt thereof.

2. (Once amended) The compound of claim 1, wherein the [residue of a] molecule comprising B-10 is directly linked to the 6-position of the compound of formula I or is directly linked to [a residue of] the b, d or e-carboxamide group of the compound of formula I.

3. (Once amended) The compound of claim 1, wherein the [residue of a] molecule comprising B-10 is linked by a linker to the 6-position of the compound of formula I or is linked by a linker to [a residue of the] b, d or e-carboxamide group of the compound of formula I.

4. (Once amended) The compound of claim 1, wherein the [residue of a] molecule comprising B-10 is linked to [a residue of] the b-carboxamide group of the compound of formula I.

5. (Once amended) The compound of claim 1, wherein the [residue of a] molecule comprising B-10 is linked to [a residue of] the d-carboxamide group of the compound of formula I.

6. (Once amended) The compound of claim 1, wherein the [residue of a] molecule comprising B-10 is linked to [a residue of] the e-carboxamide group of the compound of formula I.

8. (Once amended) The compound of claim 1, wherein the [residue of a]molecule comprising B-10 is linked to the 6-position of the compound of formula I.


25. (Twice Amended) A [residue of a] compound of formula I



26. (Once amended) The compound of claim 25, wherein the group of the formula Q-L-W-Det is linked to [a residue of]the b-carboxamide group, d-carboxamide group, e-carboxamide group or the 6-position of the compound of formula I.

27. (Once amended) The compound of claim 25, wherein the group of the formula Q-L-W-Det is linked to [a residue of]the b-carboxamide group and a second group of the formula Q-L-W-Det is linked to [a residue of]the d-carboxamide group of the compound of formula I.


29. (Once Amended) The compound of claim 25, wherein at least one chelating group is ethylenediaminetetraacetic acid (EDTA); diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA); 1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (TETA); 1,4,8,12-tetraazacyclopentadecane-N,N',N'',N'''-tetraacetic acid (15N4); 1,4,7-triazacyclononane-N,N',N''-triacetic acid (9N3); 1,5,9-triazacyclododecane-N,N',N''-triacetic acid (12N3); N-[N-[N-[(benzoylthio) acetyl]glycyl]glycyl]glycine (MAG3); or a cyclohexane-based metal chelator (DCTA) of the formula



wherein R^3 may be (C_1-C_4) alkyl or $CH_2CO_2^-$ [EDTA, DTPA, DOTA, DOTMP, TETA, MAG3, or DCTA].

30. (Once Amended) The compound of claim 25, wherein at least one chelating group is diethylenetriaminepentaacetic acid (DTPA) comprising Gd-157.

31. (Twice Amended) A [residue of a] compound of formula I




linked to [a residue of] a molecule comprising B-10; wherein the [residue of the] compound of formula I is linked to a group of the formula Q-L-W-Det, wherein X is CN, OH, CH₃, adenosyl, a molecule comprising B-10 or Q-L-W-Det; wherein

- 1) Det is a chelating group comprising a therapeutic radionuclide or a diagnostic radionuclide;
- 2) L is a linker or absent; and
- 3) Q and W are each independently -N(R)C(=O)-, -C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -S(O)₂-, -C(=O)-, -N(R)-, or a direct bond; wherein each R is independently H or (C₁-C₆)alkyl;

or a pharmaceutically acceptable salt thereof.

33. (Once amended) The compound of claim 31, wherein a molecule comprising B-10 is linked to [a residue of] a b-carboxamide group, d-carboxamide group, e-carboxamide group or the 6-position of the compound of formula I.

34. (Once Amended) The compound of claim 31, wherein at least one chelating group is ethylenediaminetetraacetic acid (EDTA); diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA); 1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (TETA); 1,4,8,12-tetraazacyclopentadecane-N,N',N'',N'''-tetraacetic acid (15N4); 1,4,7-triazacyclononane-N,N',N''-triacetic acid (9N3); 1,5,9-triazacyclododecane-N,N',N''-triacetic acid (12N3); N-[N-[N-[(benzoylthio) acetyl]glycyl]glycyl]glycine (MAG3); or a cyclohexane-based metal chelator (DCTA) of the formula



wherein R³ may be (C₁-C₄)alkyl or CH₂CO₂- [EDTA, DTPA, DOTA, DOTMP, TETA, MAG3, or DCTA].


35. (Once Amended) The compound of claim 31, wherein at least one chelating group is diethylenetriaminepentaacetic acid (DTPA) comprising Gd-157.

40. (Once amended) The compound of claim 31, wherein the [residue of a] molecule comprising B-10 is directly linked to the 6-position or to [the residue of] the b, d or e-carboxamide group of the compound of formula I.

41. (Once amended) The compound of claim 31, wherein the [residue of a] compound of formula I is linked to the [a residue of a] molecule comprising B-10 through a linker.

53. (Once amended) The compound of claim 48, wherein the linker is linked to the 6-position of the compound of formula I or is linked to the b-, d- or e-carboxamide group of the compound of formula I.

65. (Twice Amended) A [residue of a] compound of formula I



linked

- 1) to a molecule comprising B-10 or a chelating group comprising Gd-157; and
- 2) to at least one [residue] molecule of the formula Q-L-W-Det, wherein X is CN, OH, CH₃, adenosyl, a molecule comprising B-10 or Q-L-W-Det; wherein each Det is independently a chelating group comprising a metallic radionuclide; each L is independently a linker or absent; and each W and Q are each independently -N(R)C(=O)-, -C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -S(O)₂-, -C(=O)-, -N(R)-, or a direct bond; wherein each R is independently H or (C₁-C₆)alkyl;

or a pharmaceutically acceptable salt thereof.